Wait, USAID Paid for a Radical Islamic Terrorist's College Tuition?
Here's What a GOP Rep Said That Triggered Dems During a Oversight Committee...
USAID's Sloppy Trysts With Politico Pales in Comparison to This Scheme
Trump Revokes More Security Clearances
Why Elon Musk And DOGE Terrify Democrats
A Return to Charity Over Entitlements
A Quick Bible Study Vol. 254: The Lord Teaches Us an Important Lesson...
Trump Orders Secret Service to Provide 'Every Bit of Information' on the Would-Be...
Dem Senator Backs $20 Million Sesame Street Funding for Iraq Amid USAID Cuts
Two New York Firefighters Died From Illnesses Related to 9/11
DOJ Ordered to Turn Over Fani Willis Files
Biden's Energy Handouts Make USAID Look Like A Lemonade
Pete Hegseth: The Right Choice for Secretary of Defense
World War III
TikTok May Be Back Temporarily, But Kids Still Shouldn’t Be Exposed to It
Tipsheet

The CDC Director Just Gave Us an Updated Vaccine Timeline

AP Photo/Alex Brandon

We've brought you a lot of exciting vaccine news these past few weeks. And there's more of it on Tuesday. Center for Disease Control Director Robert Redfield said Americans should expect a vaccine to be rolled out very, very soon. He predicted the second week of December.

Advertisement

The next question then is, who will be receiving the first doses. He answered that too.

In an interview with Fox News anchor Dana Perino, Redfield shared that the first groups to get the vaccine will probably be "nursing home residents and then some combination of health care providers and individuals at high risk for a poor outcome."

"I do think we'll have about 40 million doses of vaccine before the end of the...year," Redfield continued. "That's enough to vaccinate 20 million people. But then it will continue through January and February and hopefully by March we'll start to see vaccine available for the general public."

Advertisement

Pfizer, who vaccine its been developing with BioNTech has produced a 95 percent efficacy rate, requested an emergency authorization from the FDA. A second vaccine candidate being produced by Moderna isn't too far behind, reporting a 94 percent effectiveness. And then a third, developed by AstraZeneca, is up to 90 percent effective.

The FDA has reportedly scheduled a meeting for Dec. 10 with its Vaccines and Related Biological Products Advisory Committee to discuss Pfizer's request.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement